Literature DB >> 18284832

Low cost in-house PCR for the routine diagnosis of extra-pulmonary tuberculosis.

D Magana-Arachchi1, J Perera, S Gamage, V Chandrasekharan.   

Abstract

SETTING: Conventional methods for the identification of mycobacteria are slow and labour intensive. DNA amplification methods offer rapid sensitive and specific diagnosis.
OBJECTIVE: To determine the feasibility of an in-house polymerase chain reaction (PCR) method to detect Mycobacterium tuberculosis in clinical samples.
DESIGN: The present study focused mainly on diagnosing extra-pulmonary tuberculosis (EPTB) using an in-house PCR method in 465 clinical samples. This study also compared the efficacy of a standard phenol-chloroform (PC) extraction procedure and the guanidine thiocyanate with diatomaceous silica (GTCS) method of DNA extraction and purification. A subsample of patients was used for the validation of results based on the final diagnosis.
RESULTS: Among 373 patients with suspected EPTB, 75 specimens were positive by PCR, four by microscopy and six by culture. Of the 25 PCR-positive patients, 95% had a final diagnosis of TB. Globally, the GTCS method was found to be superior to the PC method for DNA extraction and removal of inhibitors from clinical specimens.
CONCLUSION: The DNA amplification method was found to be significantly more sensitive and rapid compared to culture and microscopy for a reliable final diagnosis of EPTB.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18284832

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  2 in total

Review 1.  Urinary tuberculosis: modern issues.

Authors:  Gilbert J Wise
Journal:  Curr Urol Rep       Date:  2009-07       Impact factor: 3.092

2.  Development of a quantitative sandwich enzyme-linked immunosorbent assay for detecting the MPT64 antigen of Mycobacterium tuberculosis.

Authors:  Mijung Ji; Byungki Cho; Young Shik Cho; Song-Yong Park; Sang-Nae Cho; Bo-Young Jeon; Byoung-Su Yoon
Journal:  Yonsei Med J       Date:  2014-04-01       Impact factor: 2.759

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.